ImmunoGen, Inc. Announces Webcast of Presentation and Q&A at the 34th Annual J. P. Morgan Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that Daniel Junius, President and CEO, will present at the upcoming 34^th Annual J. P. Morgan Healthcare Conference in San Francisco. The presentation is scheduled for 3:00 pm PT (6:00 pm ET) on January 12, 2016.

Following the presentation, Mr. Junius will be joined by other members of ImmunoGen's management team for a question-and-answer session at 3:30pm PT (6:30 pm ET).

A webcast of the presentation and question-and-answer sessions will be accessible live through the "Investors" section of the Company's website, www.immunogen.com; a replay will be available at the same location for approximately a week.

About ImmunoGen, Inc.

ImmunoGen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics using its proprietary ADC technology. The Company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancer and other solid tumors. A number of major healthcare companies have licensed limited rights to use ImmunoGen's ADC technology to develop anticancer therapies; it is used in Roche's marketed product, Kadcyla^®. More information about the Company can be found at www.immunogen.com.

Kadcyla^® is a registered trademark of Genentech, a member of the Roche Group.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160104005110/en/

ImmunoGen, Inc.
Carol Hausner, 781-895-0600
info@immunogen.com

Source: ImmunoGen, Inc.

News Provided by Acquire Media